Wasserman T H, Slavik M, Carter S K
Cancer. 1975 Oct;36(4):1258-68. doi: 10.1002/1097-0142(197510)36:4<1258::aid-cncr2820360411>3.0.co;2-6.
The nitrosourea group of antitumor agents was developed by the Division of Cancer Treatment of the National Cancer Institute. Three nitrosoureas (BCNU, CCNU, MeCCNU) have undergone extensive clinical trials, and two of them (BCNU, CCNU) will soon become commercially available. This paper briefly considers the preclinical development of the nitrosoureas and provides an overview and comparison of the extensive clinical data. Information is given regarding any clinical differences. We discuss general conclusions drawn from the nitrosourea development.
抗肿瘤药物亚硝基脲类是由美国国立癌症研究所癌症治疗部研发的。三种亚硝基脲（卡莫司汀、洛莫司汀、司莫司汀）已进行了广泛的临床试验，其中两种（卡莫司汀、洛莫司汀）很快将上市。本文简要探讨了亚硝基脲类的临床前研发情况，并对大量临床数据进行了概述和比较。文中给出了关于任何临床差异的信息。我们讨论了从亚硝基脲类研发中得出的一般性结论。
